title: Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
abstract: Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.).
authors.affiliation: Department of Medical Affairs, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Miller
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA myra.popejoy@merck.com.
authors.forename: Myra W
authors.initials: MW
authors.lastname: Popejoy
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors.forename: Ellie
authors.initials: E
authors.lastname: Hershberger
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors.forename: Judith N
authors.initials: JN
authors.lastname: Steenbergen
authors.affiliation: Department of Surgery, University of Chicago Medical Center, Chicago, Illinois, USA.
authors.forename: John
authors.initials: J
authors.lastname: Alverdy
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity*; D000078142:Tazobactam
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008795:Metronidazole; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam